165 related articles for article (PubMed ID: 36982651)
21. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
22. Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1.
Gosepath EM; Eckstein N; Hamacher A; Servan K; von Jonquieres G; Lage H; Györffy B; Royer HD; Kassack MU
Int J Cancer; 2008 Nov; 123(9):2013-9. PubMed ID: 18688867
[TBL] [Abstract][Full Text] [Related]
23. HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Foki E; Stanisz I; Kadletz L; Kotowski U; Seemann R; Schmid R; Heiduschka G
Wien Klin Wochenschr; 2021 Jan; 133(1-2):26-31. PubMed ID: 32876741
[TBL] [Abstract][Full Text] [Related]
24. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
Stauber RH; Knauer SK; Habtemichael N; Bier C; Unruhe B; Weisheit S; Spange S; Nonnenmacher F; Fetz V; Ginter T; Reichardt S; Liebmann C; Schneider G; Krämer OH
Oncotarget; 2012 Jan; 3(1):31-43. PubMed ID: 22289787
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma.
Ow TJ; Thomas C; Fulcher CD; Chen J; López A; Reyna DE; Prystowsky MB; Smith RV; Schiff BA; Rosenblatt G; Belbin TJ; Harris TM; Childs GC; Kawachi N; Schlecht NF; Gavathiotis E
Laryngoscope; 2020 Nov; 130(11):2643-2649. PubMed ID: 31894587
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
Li C; Li R; Grandis JR; Johnson DE
Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
[TBL] [Abstract][Full Text] [Related]
27. Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling.
Sinnett-Smith J; Ni Y; Wang J; Ming M; Young SH; Rozengurt E
Am J Physiol Cell Physiol; 2014 May; 306(10):C961-71. PubMed ID: 24647541
[TBL] [Abstract][Full Text] [Related]
28. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.
Sobral LM; Sousa LO; Coletta RD; Cabral H; Greene LJ; Tajara EH; Gutkind JS; Curti C; Leopoldino AM
Mol Cancer; 2014 Feb; 13():32. PubMed ID: 24555657
[TBL] [Abstract][Full Text] [Related]
29. Integrative analyses of biomarkers and pathways for metformin reversing cisplatin resistance in head and neck squamous cell carcinoma cells.
Shanchun H; You P; Sujuan N; Xuebing Z; Yijie B; Xiaohui X; Jianming H; La N; Zhehui B; Qi L; Wulong J
Arch Oral Biol; 2023 Mar; 147():105637. PubMed ID: 36738487
[TBL] [Abstract][Full Text] [Related]
30. ΔNp63α promotes Bortezomib resistance via the CYGB-ROS axis in head and neck squamous cell carcinoma.
Zhou P; Zhang C; Song X; Zhang D; Zhu M; Zheng H
Cell Death Dis; 2022 Apr; 13(4):327. PubMed ID: 35397613
[TBL] [Abstract][Full Text] [Related]
31. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
Kikuchi S; Suzuki R; Ohguchi H; Yoshida Y; Lu D; Cottini F; Jakubikova J; Bianchi G; Harada T; Gorgun G; Tai YT; Richardson PG; Hideshima T; Anderson KC
Leukemia; 2015 Sep; 29(9):1918-27. PubMed ID: 25801913
[TBL] [Abstract][Full Text] [Related]
32. HDAC inhibitors suppress the proliferation, migration and invasiveness of human head and neck squamous cell carcinoma cells via p63‑mediated tight junction molecules and p21‑mediated growth arrest.
Kakiuchi A; Kakuki T; Ohwada K; Kurose M; Kondoh A; Obata K; Nomura K; Miyata R; Kaneko Y; Konno T; Kohno T; Himi T; Takano KI; Kojima T
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649777
[TBL] [Abstract][Full Text] [Related]
33. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC).
Zhang F; Li Y; Zhang H; Huang E; Gao L; Luo W; Wei Q; Fan J; Song D; Liao J; Zou Y; Liu F; Liu J; Huang J; Guo D; Ma C; Hu X; Li L; Qu X; Chen L; Yu X; Zhang Z; Wu T; Luu HH; Haydon RC; Song J; He TC; Ji P
Oncotarget; 2017 Feb; 8(8):12968-12982. PubMed ID: 28099902
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
Marek L; Hamacher A; Hansen FK; Kuna K; Gohlke H; Kassack MU; Kurz T
J Med Chem; 2013 Jan; 56(2):427-36. PubMed ID: 23252603
[TBL] [Abstract][Full Text] [Related]
35. Combined treatment with acetazolamide and cisplatin enhances the chemosensitivity of human head and neck squamous cell carcinoma TU868 cells.
Jia T; Ming SX; Cao QQ; Xu FL
Arch Oral Biol; 2020 Nov; 119():104905. PubMed ID: 32947166
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.
Colarossi L; Memeo L; Colarossi C; Aiello E; Iuppa A; Espina V; Liotta L; Mueller C
Proteomics Clin Appl; 2014 Dec; 8(11-12):924-31. PubMed ID: 25091122
[TBL] [Abstract][Full Text] [Related]
37. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
38. KDM5D Histone Demethylase Identifies Platinum-Tolerant Head and Neck Cancer Cells Vulnerable to Mitotic Catastrophe.
Chen TM; Huang CM; Setiawan SA; Hsieh MS; Sheen CC; Yeh CT
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982384
[TBL] [Abstract][Full Text] [Related]
39. Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma.
Ito R; Miyanishi K; Kubo T; Hamaguchi K; Osuga T; Tanaka S; Ohnuma H; Murase K; Takada K; Nagayama M; Kimura Y; Mizuguchi T; Takemasa I; Kato J
Hepatol Int; 2023 Jun; 17(3):735-744. PubMed ID: 36738397
[TBL] [Abstract][Full Text] [Related]
40. A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells.
Alhazzazi TY; Kamarajan P; Xu Y; Ai T; Chen L; Verdin E; Kapila YL
Anticancer Res; 2016 Jan; 36(1):49-60. PubMed ID: 26722027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
